Introduction
============

The market authorization (MA) procedure for medicinal products for human use is relying on their demonstrated efficacy, safety, and pharmaceutical quality (The European Parliament and the Council of the European Union, [@B24]). This applies to all medicinal products whether of chemical (e.g., blood pressure lowering diuretic) or biological (e.g., anti-inflammatory monoclonal antibody) origin. Modern biotechnology medicinal products obtain market approval through the centralized procedure as detailed in the EC Regulation 726/2004 (The European Parliament and the Council of the European Union, [@B22]).

Since 2008, a "lex specialis" -- Regulation (EC) No 1394/2007 (The European Parliament and the Council of the European Union, [@B23]) -- applies to advanced therapy medicinal products (ATMPs); these ATMPs are pharmaceuticals with high complexity (The Committee for Advanced Therapies (CAT) and the CAT Scientific Secretariat, [@B20]) linked to their development, manufacturing, or administration process.

The Regulation highlights the following:

-   It provides an explicit ATMP definition: ATMPs are gene therapy, somatic cell therapy, or tissue-engineered medicinal products.

-   An ATMP must comply with the existing MA requirements (quality, safety, and efficacy) and the post-marketing pharmaco-vigilance rules. For MA, the centralized procedure is mandatory: it aims to pool Community expertise and ensure a high level of scientific evaluation and facilitate access to market.

-   Because of the complexity of ATMPs, a new Committee for Advanced Therapies (CAT) has been installed. The CAT's main responsibilities are:

    -   The mandatory evaluation of MA applications by providing opinions to the Committee for Medicinal Products for Human Use (CHMP); the CHMP may adopt or refuse the CAT opinion.

    -   The optional scientific certification (art. 18) of quality and non-clinical data of a proposed ATMP-compound in development.

    -   The optional scientific recommendation on ATMP-classification (art. 17), prior to their clinical development.

    The CAT (The Committee for Advanced Therapies (CAT) and the CAT Scientific Secretariat, [@B20]) is a multidisciplinary scientific expert committee: it also focuses on the scientific developments in the field. There is no doubt about the huge scientific, regulatory, and ethical challenges triggered by these complex products and a specific expert committee for ATMPs is necessary to deal with these challenges (similar to the creation of the Committee on Orphan Medicinal Products for drugs used in rare diseases) and beneficial to all relevant public and private stakeholders.

-   The Tissues and Cells Directive (2004/23/EC) applies to donation, procurement and testing of human tissues and cells.

-   The Regulation defines the pre- and post-authorization requirements: GMP and GCP standards, product follow-up on efficacy and safety, risk management plan, and traceability.

-   The Regulation also provides incentives for applicants by offering scientific advice at various development steps at substantially reduced fees, mainly to small- and medium-sized enterprises and hospitals.

The aim of this ATMP -- Regulation is to offer a consolidated regulatory framework for these innovative medicines and it was designed (European Medicines Agency, [@B6]) to

> "...ensure the free movement of these medicines within the European Union (EU), to facilitate their access to the EU market, and to foster the competitiveness of European pharmaceutical companies in the field, while guaranteeing the highest level of health protection for patients."

Two *exemptions* are foreseen to the ATMP Regulation:

1.  Products, which were legally on the Community market on December 30, 2008 (when the Regulation became applicable), should be compliant to the Regulation requirements no later than December 30, 2012. These products will be withdrawn from the market afterward if no centralized MA application has been submitted and granted.

2.  Exemptions to the Regulation are also defined under the hospital exemption rule:

> "Advanced therapy medicinal products which are prepared on a non-routine basis according to specific quality standards, and used within the same Member State in a hospital under the exclusive professional responsibility of a medical practitioner, in order to comply with an individual medical prescription for a custom-made product for an individual patient, should be excluded from the scope of this Regulation whilst at the same time ensuring that relevant Community rules related to quality and safety are not undermined."

The first exemption relates to a transition period allowing existing products to evolve toward ATMP-compliance. The hospital exemption allows hospitals and medical practitioners to provide ATMP-classified products to patients, e.g., in case of high unmet medical need because there is no authorized ATMP alternative available. Concrete examples are tumor vaccines, made by hospitals for treating cancer patients having no treatment alternatives.

The hospital exemption is limited to non-routine products, custom-made for individual patients. There is discussion on the correct interpretation of these words: for instance, are autologous products *de facto* not for individual patients?

Anyway, as a consequence, ATMPs with different development tracks and quality control procedures may co-exist on the Community market satisfying different standards on efficacy, safety and quality; for hospital exemptions the Regulation requires traceability, quality, and pharmaco-vigilance standards to be "equivalent" to standards for centrally authorized products. Manufacture of ATMPs under hospital exemption has to be authorized by the appropriate member state to ensure appropriate quality. There are no efficacy criteria mentioned.

Even if there are good reasons explaining why these exemptions are needed (e.g., the realism of a transition period, the ethical need to deal with unmet medical need) the Regulation allows exemptions on the market without concrete requirement on *demonstrated* quality, efficacy, and safety.

Objectives
==========

In this work we explored whether the actual application of the Regulation on ATMPs is in line with the aim of the Regulation in terms of *guaranteeing the highest level of health protection for patients* by focusing on ATMPs and their exemptions. Health protection is understood as ensuring efficacy, safety, and pharmaceutical quality.

The aim is exploratory only: it intends to enhance the discussion on the effectiveness of the Regulation, based on early experience. This work does not pretend to provide judicious and definite answers to the complex economic and ethical issues relating to regulatory exemptions.

Methods
=======

We searched the available evidence for ATMP products being centrally authorized (EC authorized) and for their available alternatives (non-EC authorized, exemptions). We started by checking the EMA-website (European Medicines Agency, [@B9]) for authorized ATMPs till December 2011. We then searched the medical literature published on "EC authorized" and on "non-EC authorized" ATMPs. Due to the exploratory purpose, we did not make an exhaustive systematic literature search as would be required for a formal health technology assessment: our interest was not to focus on the performance of a single product *but to explore whether clinically relevant differences might exist between products*, which if it was the case would be considered as a threat to the aim of the Regulation of *guaranteeing the highest level of health protection for patients*.

Many competing interventions have not been compared directly: because the literature search ended with only one ATMP being available as EC authorized product and we did not find trials with head-to-head comparisons (see Results) between "EC authorized" and "non-EC authorized" ATMPs, we performed adjusted indirect treatment comparisons (ITCs). The on line application provided by the Canadian Agency for Drugs and Technologies in Health (CADTH; Canadian Agency for Drugs and Technologies in Health, [@B3]) was used; this public available Agency's application is based on appropriate methodology for adjusted comparisons, with an explicit user guide offering step by step assistance in the analysis. The ITC application can cope with simple and more complex (multiple comparisons) settings; in this work we simply analyzed the EC authorized ATMP with each of the non-EC authorized ATMPs based on a common comparator.

The main ITC assumption of independence among trials was achieved by excluding published study results if they originated from the same study populations.

The evidence found in the literature used different clinical end-points per trial. Only standardized treatment effects could then be used for ITC, losing the clinical relevance of the individual end-points: to cope for this loss, we considered the strength of the effect as categorized by Cohen (Valentine and Cooper, [@B25]) to approximate the clinical relevance of the results. The strength of the Cohen effect size is generally classified as follows: small effect if difference ≥0.2, medium effect if difference ≥0.5, and large effect if difference ≥0.8. We assumed that "large effects" would be considered clinically relevant effects.

No adjustment was done for multiple testing: the significance level was set at 0.05.

Results
=======

Despite the Regulation being implemented by the end of 2008, only six applications have been submitted for MA of four ATMPs (European Medicines Agency, [@B9]):

-   In June 2009 a positive opinion for MA was adopted for ChondroCelect, which is an autologous product containing chondrocytes for treatment of deep cartilage injuries of the knee.

-   In July 2009, the product Contusugene Ladenovec was withdrawn by the applicant: the product was intended for treatment of squamous cell carcinoma of head and neck.

-   In December 2009, the CAT adopted a negative opinion on the MA application of Cerepro, a gene therapy product intended for treatment of cerebral cancer (high grade glioma); the manufacturer withdrew its application in March 2010.

-   A negative CAT opinion was adopted for the MA application of Glybera in June 2011; Glybera is a gene therapy product intended for use in severe lipid metabolic disease. On re-examination of Glybera in October 2011, the CAT adopted a positive opinion but this was not endorsed by the CHMP.

Market authorization was granted by the Commission in October 2009 for ChondroCelect (TiGenix company; European Medicines Agency, [@B7]), indicated for the repair of knee cartilage defects.

Osteoarthritis (OA) is a public health concern (Clouet et al., [@B4]): during OA degenerative processes, major modifications of articular cartilage are observed at the tissue, cellular, and molecular levels. Articular cartilage, if damaged, hardly heals, and traumatic loss of cartilaginous tissue therefore may lead to the subsequent development of OA-lesions (e.g. of knee, hip...). The therapeutic options combine pharmacological treatments and tissue engineering toward regenerative medicine to induce cartilage repair.

ChondroCelect is still the only EC authorized ATMP: non-EC authorized chondrocytes for knee cartilage repair also exist. All chondrocyte products are implanted in the patient knee by a surgical technique called autologous chondrocytes implantation (ACI). In this work we will further identify these products as either CCI (for EC authorized chondrocytes, ATMP) and ACI (for non-EC authorized chondrocytes).

A simplified search in PubMed (August 18, 2011) was performed using the key words "autologous chondrocyte," limiting the search to controlled trials on human beings and further limited to papers published in English between 2008 (implementation year of the Regulation on ATMPs) and mid august 2011. The PubMed literature search resulted in 50 references (see [Appendix](#A1){ref-type="app"}).

Because the control group in the clinical development (European Medicines Agency, [@B8]) program of CCI was microfracture (a surgical micro-bleeding technique releasing stem cells), only ACI-studies including microfracture (MF) as control group could be selected for making ITC between the clinical outcome of CCI and ACI.

Across the studies a variety of clinical end-points was used with only some being considered as validated end-points for clinical research by EMA (The Committee for Advanced Therapies, [@B19]).

From the 50 references, only four papers on three studies included clinical results from ACI and MF: 45 papers were excluded because the study included only observational non-controlled data, because the study related to subgroups from the three main studies, because lack of (knee) clinical outcome results or because another comparator than MF was used. There was one systematic review (Harris et al., [@B14]) which included the results of the three identified primary studies. Moreover, the review authors took care of standardizing the clinical outcome results of the included trials which is particularly relevant because the variety of clinical and structural end-points (The Committee for Advanced Therapies, [@B19]) used in the included studies would otherwise be a hurdle to any meaningful quantitative analysis.

For making ITCs between CCI and each of the various ACI-products, the standardized results of the systematic review were subsequently used.

The review authors included seven trial reports on \>900 patients in which CCI and ACI-products were compared to MF. In our opinion, for two trials, the results of the same patient population were presented at two different lengths of follow-up: to obtain independent trial data, only one manuscript (the most recent one) per patient population was kept, resulting in five datasets for further comparison.

Indirect treatment comparisons can only be valuable if the compared patient populations across trials are similar (Jansen et al., [@B15]) with respect to modifiers of the relative treatment effect (e.g., important prognostic factors): because MF is the common comparator the appropriateness of the trial patient population with respect to the lesion size needs to be addressed. One study (reference Basad et al., [@B1] in the review) was excluded because it enrolled patients with cartilage lesions larger than 4 cm^2^, which are commonly accepted to be unsuitable for MF treatment (The Committee for Advanced Therapies, [@B19]).

Accordingly, the standardized results from four products (CCI, ACI 1--3) were compared.

The standardized direct mean treatment differences and the 95% CI of the mean differences between the various chondrocyte products and MF are as follows (extracted from p. 2226 of Harris et al., [@B45]).

  Product (reference as mentioned in the systematic review)   Standardized mean treatment difference with MF   95% Confidence interval
  ----------------------------------------------------------- ------------------------------------------------ -------------------------
  CCI (Saris et al., [@B18])                                  1.52                                             (1.03; 2.01)
  ACI 1 (Kon et al., [@B17])                                  0.76                                             (0.31; 1.21)
  ACI 2 (Basad et al., [@B2])                                 0.92                                             (−0.06; 1.82)
  ACI 3 (Knutsen et al., [@B16])                              −0.40                                            (−0.79; 0.01)

Two of the four chondrocyte products could demonstrate significant clinical benefit as compared to MF (CCI, ACI1): the standardized mean treatment difference could be classified as "large effect." The lower limit of the confidence interval of the CCI standardized clinical effect still exceeded the "large effect" threshold; both ACI2 and ACI3 products had a non-significant mean difference with MF but their confidence intervals still include "large effect" sizes.

Based on the individual study results versus MF, the ITC between the chondrocyte products could be computed and are summarized as follows (see statistical output from CADHT-tool in Appendix).

  Treatment effect   Estimate of mean Δ   95% LCL   95% UCL
  ------------------ -------------------- --------- ---------
  CCI--ACI 1         **0.76**             0.095     1.425
  CCI--ACI 2         0.60                 −0.460    1.660
  CCI--ACI 3         **1.92**             1.287     2.553
  ACI 1--ACI 2       −0.16                −1.202    0.882
  ACI 1--ACI 3       **1.16**             0.558     1.762
  ACI 2--ACI 3       **1.32**             0.298     2.342

*The bold significance relates to any statistically significant effect being 0.8 or higher, as this is the threshold of large treatment effects (Cohen effect size)*.

From the six possible ITCs four ITCs yield significant differences: CCI is significantly superior to ACI1; CCI, ACI1, and ACI2 are significantly superior to ACI3. All significant mean differences can be classified as "large" treatment effects.

Discussion
==========

Advanced therapy medicinal products are human cells and tissues or products with a genetic mode of action; they generate huge expectations but are also associated to new significant threats \[The Committee for Advanced Therapies (CAT) and the CAT Scientific Secretariat, [@B20]\] including tumorigenicity, cell (de)differentiation, and patient integration. The ATMP Regulation 1394/2007 aims to facilitate the patient access to these products and to foster the competitiveness of European pharmaceutical companies in the field, while guaranteeing the highest level of health protection for patients.

The ATMP-portfolio for which the CAT has been involved in certification, classification, and MA is available via the monthly CAT-reports (European Medicines Agency, [@B9]):

-   By the end of 2011 only one certification procedure for quality and non-clinical data has been requested (2009) and adopted (2010).

-   Fifty-three requests for ATMP-classification have been submitted of which 51 reached the recommendation stage: 46 (90.2%) have been classified ATMP.

-   Six applications for MA of four products have been evaluated leading to one authorized ATMP.

The certification procedure intends to create incentives for SMEs to develop ATMPs; the only certification procedure finished by now clearly threatens this objective. Fortunately, the number of submitted ATMP-classification requests is sufficiently large to identify the actual main areas for ATMP-development in Europe.

Among the 46 ATMP-classified products (available from website):

-   Seventeen (37.0%) are somatic cell therapy products.

-   Seventeen (37.0%) are tissue-engineered products.

-   Eleven (23.9%) are genetic therapy products.

-   One (2.1%) is classified as ATMP without further specification.

The split per therapeutic area is as follows:

  Disease: ATMP          Cancer      Cardio-vascular   Inflammatory and auto-immune   Skin       Other
  ---------------------- ----------- ----------------- ------------------------------ ---------- -----------
  Somatic cell therapy   8           1                 4                              1          3
  Tissue engineered      1           5                                                4          7
  Gene therapy           3                             1                                         7
  Total (%)              12 (26.7)   6 (13.3)          5 (11.1)                       5 (11.1)   17 (37.8)

The oncology area captures 12 ATMPs mainly classified as somatic cell (8) therapy. Cell compounds for treatment of debilitating inflammatory (e.g., multiple sclerosis) or auto-immune diseases (e.g., pancreatitis) and tissue-engineered products for use in severe cardiovascular disease (e.g., myocardial infarction) or skin disease (mainly treatment of burn wounds) are in development; applications are studied in metabolic disease, ophthalmology, bone, and cartilage disease, but also in muscular, and neurological disease (e.g., Parkinson disease).

Clearly, these are therapeutic areas with a huge disease burden, linked to a high unmet medical need in which ATMPs may be of value by their unique mode of action, aiming at regenerating cell functionality, and tissue integrity.

After 4 years the net outcome of the ATMP Regulation 1394/2007 is still limited as only one ATMP has been authorized and only one request for certification has been finalized, despite the fact that already 46 compounds have been classified as ATMP. In the US, the Center for Biologics Evaluation and Research (CBER; Food and Drug Administration, [@B10]) within FDA regulates biological products for human use, both investigational and licensed. CBER regulates biological products including gene therapy, human tissue, and cells under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. By now, no gene therapy has been authorized to market but various human tissue (Food and Drug Administration, [@B11]) and cell products are authorized including the autologous cellular immunotherapy product Provenge (Dendreon company) for treatment of prostate cancer and the cultured chondrocytes product Carticel (Genzyme company). There is no "lex specialis."

Exemptions, specific to the European Regulation include a temporary exemption (till end of 2012) for products existing prior to the implementation of the Regulation and a permanent hospital exemption for non-routinely made products for individual patients. In this work we aimed to verify whether different development tracks for these complex medicinal products are not putting the patient health protection (defined as ensuring efficacy, safety, and pharmaceutical quality) at risk.

The only ATMP authorized in the Community market is a medicinal product containing chondrocytes for knee cartilage regeneration.

Based on the literature search on the "EC authorized" and "non-EC authorized" chondrocyte products, ITC could be made between four different products. Our results indicate statistically significant and clinically relevant differences in efficacy exist between these four cell products.

The Regulation 1394 is based on the assumption that "EC authorized" and exempted ATMPs provide similar health patient benefit. But based on our indirect results, the probability of a healthy patient outcome is strongly dependent on the product administered; this puts the exemption rule of the Regulation under pressure.

From a pharmacological point of view, similar (the highest) health patient benefit among exempted and non-exempted ATMPs is assuming there would be a class effect (acknowledging this may be a difficult concept for autologous products). But even for a class of conventional medicinal products like ACE-inhibitors, quantitative differences altering the therapeutic benefits for specific patient populations may exist as shown by Furberg ([@B12]); the author's conclusion was that untested drugs of a class should be considered unproven drugs. If this is the case for conventional medicinal products, how confident can we then be in assuming that the highest health benefit will be ensured between more complex medicinal products?

Finally, more specifically in the orthopedic surgery field, the review by Vavken and Samartzis ([@B26]) did mention: "...Also ACI can hardly be seen as one, standardized treatment, due to technical differences, and inter-patient variation in cell quality."

Based on the above, in the therapeutic area of orthopedic surgery, there is evidence to say clinically relevant differences in health outcome exist between the authorized ATMP and the exemption products.

This study has many limitations. Only one medicinal product could be investigated despite the Regulation being applicable from the end of 2008.

The evidence on different health outcome benefits between the ATMP and its exemption products is based on ITC from one recent systematic review in the orthopedic surgery field. There is a lack of controlled trials with acceptable quality in this area (Hanzlik et al., [@B13]): in a review of all articles published in The Journal of Bone and Joint Surgery in the years 1975, 1985, 1995, and 2005 the percentage of Level-I studies increased from 4% in 1975 to 21% in 2005. Despite this positive trend for increasing the percentage of high level evidence trials there is still substantial opportunity for improvement.

The individual clinical trial end-points were transformed into one standardized outcome affecting the interpretation of clinical relevance: to deal with this, we used the common cut-off for large treatment effects to identify clinical relevant effects.

We analyzed efficacy and did not focus on other elements of patient health benefit like safety or pharmaceutical quality. Investigating differences in safety issues might be very hard because of the small number of patients enrolled in the considered studies (maximum of 118 patients randomized): the estimate of the incidence of adverse events for any compound will lack precision. Differences in pharmaceutical quality could not be investigated because of lack of public available documentation. It is a clear advantage of EC centrally authorized medicinal products that important regulatory documentation is easily available: the summary of product characteristics (SPC) and the European public assessment report (EPAR) provide relevant insights to patient and health care worker on efficacy, safety, and pharmaceutical quality of the medicinal product. The extent of documentation on non-EC authorized products is differing between member states, delivering companies or hospitals, and may be hard to obtain for any external party.

We did not analyze how exemptions to ATMPs may affect the internal market functioning because of the limited experience with only one ATMP available. Obviously differences in development track will yield differences in the necessary R&D resources, which may result in substantial product price differences: this is a hurdle for the applicant submitting a centrally authorized ATMP when lower priced exempted alternatives are on the market. In many member states a price premium can only be granted if added therapeutic value compared to the alternative has been demonstrated. But this direct comparison will probably lack, as it is the case for the 1st ATMP containing cultured chondrocytes: the design section of the CAT-Reflection Paper (The Committee for Advanced Therapies, [@B19]) in this field clearly specifies "*licensed products"* as valid comparators that can be used in controlled trials. It further states "...However, the use of a non-authorized medicinal product is problematic as it has not been validated for clinical use and the quality of the product has not been assessed."

Valid approaches to adjusted ITC will be necessary but the acceptability of indirect evidence may be different between competent authorities increasing the 4th hurdle for ATMPs.

As the European Pharmaceutical Forum and the European Transparency Directive (The Council of the European Communities, [@B21]; European Commission, [@B5]) explicitly ask competent authorities on pricing and reimbursement to take decisions based on objective and verifiable criteria and to be well aligned with the estimated value of medicines, the question may arise how these member states will determine the relative value of an ATMP in comparison to exempted alternatives with assumed but unproven effect.

In conclusion, based on the analysis of the relative efficacy of the only EC authorized ATMP and its exempted alternatives, there is evidence against the Regulation 1394/2007 assumption of ensuring the highest level of patient health protection is maintained among each of these products. The ethical need for exemption must be balanced with the upcoming evidence of differences in health outcome between EC authorized and non-EC authorized ATMP products. The scheduled review by the Commission by the end of 2012 of the application of the Regulation should include an assessment of the likelihood of similar health outcome among ATMPs with different development tracks.
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